apceth Names Dr Stefanos Theoharis Chief Business Officer
News Sep 05, 2013
Cell-therapy company, apceth GmbH, has announced the expansion of its senior management team with the appointment of Dr Stefanos Theoharis as Chief Business Officer.
In this newly created role, Dr Theoharis will lead apceth’s business development and business operations to maximize the value of the company’s world class clinical and preclinical pipeline. He will also promote the continued expansion of apceth’s GMP manufacturing business.
Dr Theoharis brings broad experience in the life science sector from roles in leading pharma companies, biotech, investment banking and academia. He joins apceth from Antisense Pharma, where he was Head of Business Development. Before that, he held the position of Business Development Director with Roche, where he focused on deals and alliances in Emerging Technologies. He was previously an M&A Analyst in the Life Science team for Lazard.
Dr Theoharis holds a PhD in Cell and Gene Therapy from Imperial College London, where he subsequently worked as a Research Fellow, as well as acting as a transfer consultant for the London Technology Network.
“Apceth is about to start the world’s first clinical trial with genetically modified mesenchymal stem cells in cancer indications, while our trial in Critical Limb Ischemia is advancing, so it’s a very exciting time for us to welcome Stefano to the team”, said Christine Guenther, CEO of apceth. “His experience will complement our management team and help drive apceth forward.”
Switch Discovered to Convert Blood Vessels to Blood Stem Cells During Embryonic DevelopmentNews
Findings could aid research into creating new blood cells for transplants and understanding cancer metastasis.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018